Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Carboplatin/paclitaxel chemotherapy following docetaxel in metastatic CRPC is well tolerated with favorable PSA response rates and survival. This combination is a viable option after progression on docetaxel-based therapy.